看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
: b1 {) E* H, \; |0 v* ?5 q0 \1 F% B: M7 d
# O+ Q: N8 h+ @" _" S4 e/ @8 NCurrently available feasibility data for possible combination strategies. * B) [, a! w/ y5 O% ~" F; j6 u
————————————————————————————————
) @& u( ^$ \. m9 p# lCombination Feasibility according to preliminary data
4 o1 q# l* C/ a3 {$ b! r——————————————————————————————————
7 @5 |& h$ n4 [% T/ fBevacizumab + sorafenib Yes, reduced dose
% J) @5 q9 s; f% b* @Bevacizumab + sunitinib† No . u7 ^# S$ M( r( M- r
Bevacizumab + temsirolimus Yes
% O; ~- N* V; H" s+ KBevacizumab + everolimus Yes
3 r% Y9 u$ C* A; BSorafenib + sunitinib ?
( w N( J; { U( s% u5 ~Sorafenib + temsirolimus Yes, reduced dose ! t( l9 H H; m) L/ }; W
Sorafenib + everolimus Yes, reduced dose
7 N7 I& L! p( x, N. A$ X1 USunitinib + temsirolimus† No " M5 j/ }6 c( B! g. j
Sunitinib + everolimus ? 0 x8 W& r F! G! | C$ V8 z( G7 F& O
Temsirolimus + everolimus ? . n) S! n/ |* P2 L9 [
————————————————————
: t" P# G U- j A†Led to US FDA warning.; {! I: e7 w' |; f
?: As yet unattempted combination.
4 N- J( N% T' S, }) R |